博拓生物1月23日公告，预计2025年年度归母净利润4500万元左右，同比减少73.45%左右。 ...

归属于母公司所有者的扣除非经常性损益的净利润为2400.00万元左右，与上年同期(法定披露数据)相 比，将减少9528.76万元左右，同比减少79.88%左右。 格隆汇1月23日丨博拓生物(688767.SH)公布，经杭州博拓生物科技股份有限公司财务部门初步测算，预 计2025年年度实现归属于母公司所有者的净利润为4500.00万元左右，与上年同期(法定披露数据)相比， 将减少12,451.55万元左右，同比减少73.45%左右。 ...

Summary of the Conference Call for Botao Bio Company Overview - **Company**: Botao Bio - **Industry**: Brain-Computer Interface (BCI) and In Vitro Diagnostics (IVD) Key Points Strategic Positioning in Brain-Computer Interface - Botao Bio views the brain-computer interface sector as a second growth curve and has invested in two companies: Qingshi Yongjun (invasive) and Haoshi Tianhui (non-invasive) to cover different technological paths for depression treatment [2][4] - Haoshi Tianhui focuses on non-invasive BCI combined with AI technology, capable of assessing depression or anxiety in 90 seconds and providing personalized music therapy, currently applied in hospitals and schools, with Botao holding a 16% stake [2][6] - Qingshi Yongjun specializes in invasive BCI for treatment-resistant depression, currently conducting clinical trials with significant results from the first patient treated with deep brain stimulation (DBS) [2][7] Clinical Trials and Progress - The first patient in the invasive BCI clinical trial has been followed for nearly five years without relapse, indicating long-term efficacy [2][11] - A new round of clinical trials started in June 2025, with 4 patients enrolled so far, and plans to enroll 100 patients by the end of 2026 [2][12] Financial and Investment Plans - Botao Bio plans to increase its stake in Qingshi Yongjun to over 10% by the end of 2026 to support formal clinical registration and related costs [2][14] - The company maintains a strong cash flow and is actively seeking suitable projects for investment in the healthcare sector to drive innovation and commercialization [3][9] Market Potential and Product Development - The global market for depression treatment is substantial, with approximately 300 million patients worldwide, including 95 million in China [7] - Botao Bio has developed a personalized depression brain network technology that is considered leading both domestically and globally [10] Future Expansion Plans - The company aims to expand its BCI strategy beyond current projects to include other indications such as Parkinson's and epilepsy [8] - Botao Bio is committed to deepening its industrial cooperation in the BCI field, supported by national policies and local government collaboration [19] Collaborations and Partnerships - Botao Bio's collaboration with Qingshi Yongjun is positioned as a strategic investment rather than a financial one, focusing on registration systems and market channels, particularly in domestic and international markets [20] - The company also plans to collaborate with Haoshi Tianhui in sales, production, and registration [20] New Product Developments - Botao Bio is advancing new products in the microfluidics technology sector, which are gradually obtaining certifications and being promoted in the market [21] - The company expects significant milestones in 2026, including progress in microfluidic product certifications and further developments in the BCI field [22]

Core Viewpoint - The company is focusing on expanding its business in the European market by prioritizing product registration under the EU IVDR regulations [2] Group 1: Business Strategy - The company is developing a systematic and multi-dimensional market operation system to enhance its presence in Europe [2] - The global market is divided into several core regions, including Europe, to create a networked layout covering major economies [2] - A sales manager responsibility system is implemented in each sales region, focusing on market development, customer acquisition, and after-sales support [2] Group 2: Sales Model - The company employs a combination of ODM (Original Design Manufacturer) and OBM (Original Brand Manufacturer) sales models to optimize its sales strategy [2]

Core Insights - The investment agreement between Botao Bio's subsidiary Botai Zhito and Hangzhou Haoshi Tianhui marks a significant step in the brain-computer interface (BCI) industry, enhancing the commercial viability of the sector [1][2] Group 1: Investment and Strategic Development - Botai Zhito has completed a strategic investment in Haoshi Tianhui, becoming the sole investor in this financing round [1] - This investment complements Botao Bio's previous strategic stake in Qingshi Yongjun, establishing a dual technology path in both invasive and non-invasive BCI [2] Group 2: Company and Product Overview - Haoshi Tianhui is an innovative high-tech enterprise focused on AI in healthcare, with a strong founding team possessing overseas entrepreneurial experience and deep technical expertise [2] - The company's core AI and non-invasive BCI products aim to create a closed-loop service for various mental health issues, including depression and anxiety, through assessment, intervention, and feedback [2] Group 3: Financial Projections - Revenue forecasts for the company from 2025 to 2027 are projected at 496 million, 693 million, and 887 million yuan, reflecting a year-on-year change of -11.42%, +39.78%, and +28.11% respectively [3] - The net profit attributable to the parent company is expected to be 60 million, 158 million, and 215 million yuan for the same period, with year-on-year changes of -64.49%, +162.50%, and +35.95% respectively [3]

杭州博拓生物科技股份有限公司 2026 年第一次临时股东会会议资料 杭州博拓生物科技股份有限公司 2026 年第一次临时股东会会议资料 杭州博拓生物科技股份有限公司 2026 年第一次临时股东会会议须知 为维护广大投资者的合法权益，保障股东在本次股东会期间依法行使权利， 根据《公司法》、中国证监会《上市公司股东会规则》和公司《股东会议事规则》 等有关规定，特制定本会议须知： 一、公司负责本次股东会的议程安排和会务工作，为确认出席会议的股东或 其代理人或其他出席者的出席资格，会议工作人员将对出席会议者的身份进行必 要的核对工作，请被核对者给予配合。 证券代码：688767 证券简称：博拓生物 杭州博拓生物科技股份有限公司 2026 年第一次临时股东会会议资料 2026 年 1 月 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示身份证明文件或营业执照/注册证书复印件（加盖公章）、 授权委托书等，上述登记材料均需提供复印件一份，个人登记材料复印件须个人 签字，法定代表人证明文件复印件须加盖公司公章，经验证后方可出席会议。会 议开始后，由会议主持人宣布现场出席会议的股东人数及 ...

Summary of the Conference Call for Botao Bio Company Overview - **Company**: Botao Bio - **Investment**: Strategic investment in Qingshi Yongjun, focusing on brain-computer interface (BCI) technology for treatment of treatment-resistant depression (TRD) [2][3] Key Industry Insights - **Market Potential**: Approximately 20 million patients globally suffer from treatment-resistant major depression, indicating a significant market opportunity [2][8] - **Current Treatment Landscape**: Existing treatments for TRD are largely ineffective, creating a gap for innovative solutions like those being developed by Qingshi Yongjun [8][9] Core Points and Arguments - **Strategic Investment**: Botao Bio's investment in Qingshi Yongjun is not purely financial; it aims to enhance R&D capabilities in the BCI field [2][3] - **Clinical Trials**: Initial clinical trial data shows promising results, with one patient reportedly cured after one week of treatment [2][6] - **Future Clinical Trials**: A formal clinical trial involving 100 patients is expected to start in the second half of 2026, pending successful preliminary results [7] - **Regulatory Pathway**: Botao Bio plans to obtain Class III medical device registration by around 2029, with a focus on promoting the product through top-tier hospitals [2][10] Financial Aspects - **Projected Costs**: Estimated treatment costs are around 500,000 CNY, with a product factory price of approximately 200,000 CNY [11] - **Funding Requirements**: Anticipated clinical and registration costs are over 100 million CNY, with plans for further investment in Qingshi Yongjun [12] Collaboration and Market Strategy - **Synergy with Qingshi Yongjun**: Both entities share a unified core team and are integrated with Zhejiang University’s research institute, enhancing their collaborative potential [4][5] - **Market Expansion Plans**: Botao Bio aims to expand into international markets, including obtaining FDA certification for the U.S. market [10][11] Additional Insights - **Impact of External Factors**: The suspension of U.S.-China tariffs and currency fluctuations have positively influenced Botao Bio's U.S. business outlook [4][18] - **IVD Industry Outlook**: The IVD industry is expected to show slight improvement in 2026, although competition remains fierce [21] - **Microfluidics Development**: Botao Bio is investing in microfluidics technology, targeting revenue goals of 500 million to 1 billion USD in the coming years [20] Conclusion Botao Bio is strategically positioning itself in the burgeoning field of brain-computer interfaces, particularly for treatment-resistant depression, with a robust plan for clinical trials and market expansion. The company is leveraging its financial resources and collaborative partnerships to navigate regulatory pathways and capitalize on significant market opportunities.

Group 1 - The company, Botao Bio, announced that it will hold its first extraordinary general meeting of shareholders in 2026 on January 26 [2]

证券日报网讯 1月9日，博拓生物发布公告称，公司第四届董事会第四次会议审议通过《关于预计2026 年度日常关联交易的议案》《关于修订及修订、新增部分制度的议案》《关于提请召开公司2026年第一 次临时股东会的议案》。 （文章来源：证券日报） ...

杭州博拓生物科技股份有限公司 内部审计制度 杭州博拓生物科技股份有限公司 第二条 本制度所称内部审计，是指由公司内部审计机构或人员，对其内 部控制和风险管理的有效性、财务信息的真实性和完整性以及经营活动的效率和 效果等开展的一种评价活动。 第三条 本制度所称内部控制，是指公司董事会、审计委员会、高级管理人 员及其他有关人员为实现下列目标而提供合理保证的过程： （一）遵守国家法律、法规、规章及其他相关规定； （二）提高公司经营的效率和效果； （三）保障公司资产的安全。 内部审计制度 第一章 总 则 第一条 为了加强杭州博拓生物科技股份有限公司（以下简称"公司"）的 内部审计工作，根据《中华人民共和国会计法》《中华人民共和国审计法》《杭 州博拓生物科技股份有限公司章程》和有关法律法规以及股份有限公司规范化的 要求，结合本公司实际，制定本制度。 第四条 内部审计遵循"独立、客观、公正"的原则，保证其工作合法、 合理有效，完善公司内部约束机制，加强内部管理，提高经济效益。 第五条 公司董事会对内部控制制度的建立健全和有效实施负责，重要的 内部控制制度应当经董事会审议通过。 公司董事、高级管理人员、公司各部门及各控股子 ...